. Author manuscript; available in PMC: 2014 Oct 20.

Published in final edited form as: Hepatology. 2010 Apr;51(4):1168–1175. doi: 10.1002/hep.23477

Table 4. KIR and HLA-C Associations in the Interferon-Treated Individuals.

	SVR n (%)	No SVR n (%)	P Value (Pc)	OR (95% CI)
Number of patients	107	101
KIR2DL2	54 (50.5)	60 (59.4)	0.20
KIR2DL3	98 (91.6)	90 (89.1)	0.54
Group 1 HLA-C	94 (87.9)	76 (75.2)	0.02 (>0.1)	2.4 (1.1-5.3)
Group 2 HLA-C	63 (58.9)	67 (66.3)	0.27
KIR2DL2-C1	46 (43.0)	40 (39.6)	0.62
KIR2DL3-C1	88 (82.2)	68 (67.3)	0.01 (0.1)	2.3 (1.2-4.3)
KIR2DL3-C1 homozygous	18 (16.8)	13 (12.9)	0.64
KIR2DL3-C1 heterozygous	70 (65.4)	55 (54.4)	0.11